CLINICAL RESEARCH: SAFETY ISSUE
Mode of Death in Advanced Heart Failure
The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial
Peter Carson, MD, FACC*,*,
Inder Anand, MD, FACC ,
Christopher O’Connor, MD, FACC ,
Brian Jaski, MD, FACC ,
Jonathan Steinberg, MD, FACC||,
Amy Lwin, RN¶,
JoAnn Lindenfeld, MD, FACC#,
Jalil Ghali, MD, FACC**,
Jodi H. Barnet, MS,
Arthur M. Feldman, MD, PhD, FACC and
Michael R. Bristow, MD, PhD, FACC#
* Veterans Affairs Medical Center, Washington, DC
Division of Cardiology, Veterans Affairs Medical Center, Minneapolis, Minnesota
Division of Cardiology, Duke University, Durham, North Carolina
Advanced Heart Failure and Cardiac Transplant Programs, Sharp Memorial Hospital, San Diego, California
|| Division of Cardiology, St. Luke’s-Roosevelt Hospital, New York, New York
¶ Clinical Cardiovascular Research, Gaithersburg, Maryland
# Division of Cardiology, University of Colorado, Denver, Colorado
** Louisiana State University Medical Center, Shreveport, Louisiana
University of Wisconsin, Madison, Wisconsin
Jefferson Medical College, Philadelphia, Pennsylvania
Manuscript received March 1, 2005;
revised manuscript received August 24, 2005,
accepted September 8, 2005.
* Reprint requests and correspondence: Dr. Peter E. Carson, Division of Cardiology, Veterans Affairs Medical Center, 50 Irving Street NW, Washington, DC 20422 (Email: Peter.Carson{at}med.va.gov).
OBJECTIVES: The aim of this study was to evaluate the mode of death in patients with advanced chronic heart failure (HF) and intraventricular conduction delay treated with optimal pharmacologic therapy (OPT) alone or OPT with biventricular pacing to provide cardiac resynchronization therapy (CRT) or CRT + an implantable defibrillator (CRT-D).
BACKGROUND: Limited data are available on mode of death in advanced HF. No data have existed on mode of death in these patients who also have an intraventricular conduction delay and are treated with CRT or CRT-D.
METHODS: Using prespecified definitions and source materials, seven cardiologists assessed mode of death among the 313 deaths that occurred in the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial.
RESULTS: A primary cardiac cause was present in 78% of deaths. Pump failure (44.4%) was the most common mode of death followed by sudden cardiac death (SCD) (26.5%). Compared with OPT, CRT-D significantly reduced the number of cardiac deaths (38%, p = 0.006), whereas CRT alone was associated with a non-significant 14.5% reduction (p = 0.33). Both CRT and CRT-D tended to reduce pump failure deaths (29%, p = 0.11 and 27%, p = 0.14, respectively). The CRT-D significantly reduced SCD (56%, p = 0.02), but CRT alone did not.
CONCLUSIONS: Pump failure deaths are the predominant mode of death in patients with advanced HF and are modestly reduced by both CRT and CRT-D. Only CRT-D reduced SCD and thus produced a favorable effect on cardiac mortality.
|
Abbreviations and Acronyms
| | CI = confidence interval | | COMPANION = Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure trial | | CRT = cardiac resynchronization therapy | | CRT-D = cardiac resynchronization therapy with defibrillator | | HF = heart failure | | HR = hazard ratio | | ICD = implantable cardioverter-defibrillator | | NYHA = New York Heart Association | | OPT = optimal pharmacologic therapy | | SCD = sudden cardiac death |
|
This article has been cited by other articles:
|
|
|
|
 
S. Setoguchi, A. Nohria, J. A. Rassen, L. W. Stevenson, and S. Schneeweiss
Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure
Can. Med. Assoc. J.,
March 17, 2009;
180(6):
611 - 616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Anand, P. Carson, E. Galle, R. Song, J. Boehmer, J. K. Ghali, B. Jaski, J. Lindenfeld, C. O'Connor, J. S. Steinberg, et al.
Cardiac Resynchronization Therapy Reduces the Risk of Hospitalizations in Patients With Advanced Heart Failure: Results From the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Trial
Circulation,
February 24, 2009;
119(7):
969 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Hansky, J. Vogt, A. Zittermann, H. Guldner, J. Heintze, U. Schulz, D. Horstkotte, G. Tenderich, and R. Korfer
Cardiac resynchronization therapy: long-term alternative to cardiac transplantation?
Ann. Thorac. Surg.,
February 1, 2009;
87(2):
432 - 438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Orso, S. Baldasseroni, G. Fabbri, L. Gonzini, D. Lucci, C. D'Ambrosi, M. Gobbi, G. Lecchi, S. Randazzo, G. Masotti, et al.
Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure
Eur J Heart Fail,
January 1, 2009;
11(1):
77 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Mehta, S. W. Dubrey, H. F. McIntyre, D. M. Walker, S. M.C. Hardman, G. C. Sutton, T. A. McDonagh, and M. R. Cowie
Mode of death in patients with newly diagnosed heart failure in the general population
Eur J Heart Fail,
November 1, 2008;
10(11):
1108 - 1116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Silka and Y. Bar-Cohen
Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD?: Patients With Congenital Heart Disease and a Systemic Ventricular Ejection Fraction Less Than 30% Should Undergo Prophylactic Implantation of an Implantable Cardioverter Defibrillator
Circ Arrhythm Electrophysiol,
October 1, 2008;
1(4):
298 - 306.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ding, W. Hua, H. Niu, K. Chen, and S. Zhang
Primary prevention of sudden cardiac death using implantable cardioverter defibrillators
Europace,
September 1, 2008;
10(9):
1034 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Patel and J. T. Heywood
Mode of Death in Patients With Systolic Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics,
June 1, 2007;
12(2):
127 - 136.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. D. Burkhardt and B. L. Wilkoff
Interventional Electrophysiology and Cardiac Resynchronization Therapy: Delivering Electrical Therapies for Heart Failure
Circulation,
April 24, 2007;
115(16):
2208 - 2220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lindenfeld, A. M. Feldman, L. Saxon, J. Boehmer, P. Carson, J. K. Ghali, I. Anand, S. Singh, J. S. Steinberg, B. Jaski, et al.
Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients With New York Heart Association Class IV Heart Failure
Circulation,
January 16, 2007;
115(2):
204 - 212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Yao, N. Freemantle, M. J. Calvert, S. Bryan, J.-C. Daubert, and J. G.F. Cleland
The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator
Eur. Heart J.,
January 1, 2007;
28(1):
42 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Saxon, M. R. Bristow, J. Boehmer, S. Krueger, D. A. Kass, T. De Marco, P. Carson, L. DiCarlo, A. M. Feldman, E. Galle, et al.
Predictors of Sudden Cardiac Death and Appropriate Shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial
Circulation,
December 19, 2006;
114(25):
2766 - 2772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ward, S. Guo, and J. J. Caro
Cost-Effectiveness of Cardiac Resynchronization Therapy
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1283 - 1283.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Saxon
More is better with cardiac resynchronization therapy--but is it enough?
Eur. Heart J.,
August 2, 2006;
27(16):
1891 - 1892.
[Full Text]
[PDF]
|
|
|
|
